ESTIMATED
05/14/2024
05/14/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.69 | -$0.69 | -$0.69 |
Q2 2024 | 4 | -$0.53 | -$0.50 | -$0.52 |
Q3 2024 | 1 | -$0.46 | -$0.46 | -$0.46 |
Q4 2024 | 1 | -$0.42 | -$0.42 | -$0.42 |
Q1 2025 | 2 | -$0.30 | -$0.30 | -$0.30 |
Q2 2025 | 2 | -$0.30 | -$0.30 | -$0.30 |
Q3 2025 | 2 | -$0.25 | -$0.25 | -$0.25 |
Q4 2025 | 2 | -$0.25 | -$0.25 | -$0.25 |
Arcutis Biotherapeutics, Inc. last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-0.32 earnings per share for the quarter, topping analysts' consensus estimates of $-0.6 by $0.28. The company had revenue of 49.57 M for the quarter and had revenue of 59.61 M for the year. Arcutis Biotherapeutics, Inc. has generated $-4 earnings per share over the last year ($-3.78 diluted earnings per share) and currently has a price-to-earnings ratio of -4.9. Arcutis Biotherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/14/2024 | Q1 2024 | -$0.60 | -$0.32 | 0.28 | $15.18 M | $49.57 M | 02/27/2024 | Q4 2023 | -$0.65 | -$0.72 | -0.07 | $11.41 M | $13.53 M | 11/03/2023 | Q3 2023 | -$0.90 | -$0.73 | 0.17 | $38.11 M | 08/08/2023 | Q2 2023 | -$1.22 | -$1.16 | 0.06 | $5.19 M | 05/09/2023 | Q1 2023 | -$1.30 | -$1.30 | 0 | $3.14 M | $2.78 M | 02/28/2023 | Q4 2022 | -$1.37 | -$1.24 | 0.13 | $2.20 M | $2.96 M | 11/08/2022 | Q3 2022 | -$1.54 | -$1.94 | -0.4 | $725,000 | 08/04/2022 | Q2 2022 | -$1.38 | -$1.34 | 0.04 | $0 | 05/05/2022 | Q1 2022 | -$1.42 | -$1.31 | 0.11 | $0 | 02/22/2022 | Q4 2021 | -$1.41 | -$1.42 | -0.01 | $0 | 11/04/2021 | Q3 2021 | -$1.09 | -$1.14 | -0.05 | $0 | 08/05/2021 | Q2 2021 | -$0.91 | -$0.84 | 0.07 | $0 | 05/06/2021 | Q1 2021 | -$0.76 | $0 | 02/16/2021 | Q4 2020 | -$0.89 | -$0.72 | 0.17 | $0 | 11/05/2020 | Q3 2020 | -$0.95 | -$1.01 | -0.06 | $0 | 08/11/2020 | Q2 2020 | -$0.84 | -$0.94 | -0.1 | $0 | 05/12/2020 | Q1 2020 | -$0.92 | -$1.15 | -0.23 | $0 | 03/19/2020 | Q4 2019 | -$9.21 | -$0.52 | 8.69 | $0 | 09/29/2019 | Q3 2019 | -$0.80 | $0 | 06/29/2019 | Q2 2019 | -$0.46 | $0 |
---|
A. Arcutis Biotherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. In the previous quarter, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported $-0.32 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.6 by $0.28.
A. The conference call for Arcutis Biotherapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Arcutis Biotherapeutics, Inc.'s latest earnings report can be read online.
A. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a recorded annual revenue of $59.61 M.
A. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a recorded net income of $59.61 M. Arcutis Biotherapeutics, Inc. has generated $-3.78 earnings per share over the last four quarters.
A. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a price-to-earnings ratio of -4.9 and price/earnings-to-growth ratio is -0.2.